Passage Bio

Passage Bio is a biotechnology and health care company headquartered in the United States that aims to revolutionize the treatment of central nervous system (CNS) disorders. Founded in 2018, the company has garnered significant attention and financial backing, including a substantial $154.00M Post-IPO Equity investment on 21 January 2021. The company's slogan "World-class genetic medicines company that’s changing the future of CNS disease" reflects its commitment to leveraging genetic medicine to address the challenges associated with CNS disorders. Passage Bio's collaborative efforts with the University of Pennsylvania's Gene Therapy Program and Orphan Disease Center demonstrate its strategic approach to gene therapy development. Passage Bio's portfolio includes optimized gene therapy programs targeting debilitating CNS diseases such as GM1 gangliosidosis, Krabbe disease, and Frontotemporal dementia. The company's location in Philadelphia, PA, coupled with its new laboratory at the Princeton West Innovation Campus in Hopewell, New Jersey, positions it within a vibrant scientific and medical research community. Overall, Passage Bio's focus on genetic medicine and its substantial post-IPO equity investment indicate a promising trajectory in its efforts to transform the future of CNS disease treatment.